NCT07052448

The Efficacy of Sequential RT After Triple Therapy for uHCC

The Efficacy of Sequential Radiotherapy After the Combination of Transcatheter Arterial Chemoembolization With Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 35 (estimated)
• Sponsor: Fujian Provincial Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and many patients fail to achieve complete necrosis of the lesions after treatment. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies	sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies

Timeline

• Start date: 2020-11-01
• Primary completion: 2026-06-01
• Completion: 2026-06-30
• First posted: 2025-07-04
• Last updated: 2025-07-04

Locations

1 site across 1 country: China